Wang DY, Moorhadian MC, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, Mckee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology. 2018, Oct. PMID: 30546965

Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. Journal for ImmunoTherapy of Cancer. 2019, Dec;7:353. PMCID: PMC6918622

Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. J Clin Oncol. 2020, Sep. PMID: 32491962

Gupta S, Belouali A, Shah NJ, Atkins MB, Madhavan S. Automated identification of patients with immune-related adverse events from clinical notes using word embedding and machine learning. JCO Clinical Cancer Informatics. 2021, Jan;5:541-549. PMCID: PMC8462565

Baldelli E, Hodge KA, Bellezza G, Shah NJ, Gambara G, Sidoni A, Mandarano M, Ruhunusiri C, Dunetz B, Abu-Khalaf M, Wulfkuhle J, Gallagher RI, Liotta L, Bono JD, Mehra N, Riisnaes R, Ravaggi A, Odicino F, Sereni AI, Blackburn M, Zupa A, Improta G, Demsko P, Crino L, Ludovini V, Gioccone G, Petricoin EF, Pierobon M. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. Journal for Immunother Cancer. 2021, Oct. PMID: 34620701

Shah NJ, Zhang D, Cook M, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins MB, Braithwaite D. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers. 2021, Dec. PMCID: PMC8657283

• Correction: Zhang D, Shah NJ, Cook M, Blackburn M, Serzan MT, Advani S, Potosky AL, Madhavan S, Belouali A, Atkins MB, Braithwaite D. Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109. Cancers. 2022, Sep;14(18):4525. PMID: 36139703

Shah NJ, Cook MR, Wu T, Lev-Ari S, Blackburn MJ, Serzan MT, Alaoui A, Ahn J, Atkins MB. The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids. J Natl Compr Canc Netw. 2022, Jul;7. PMID: 35830888

Lev-Ari S, Serzan M, Wu T, Ip A, Pascual L, Sinclaire B, Adams S, Marafelias M, Ayyagari L, Gill SK, Ma B, Zaemes JP, Della Pia A, Alaoui A, Madhavan S, Belouali A, Pecora A, Ahn J, Atkins MB, Shah NJ. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study. Cancer. 2023;129(12):1885-1894.

Zhang Y, Ari SL, Gupta S, Zaemes J, Shah NJ, Alaoui A, Madhavan S, McGarvey P, Atkins MB. Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events. Journal for ImmunoTherapy of Cancer. 2023;11:doi: 10.1136/jitc-2023-SITC2023.1317

Zaemes J, Ari SL, Pascual L, Jegede OA, Arias-Orozco N, Sinclaire B, DellaPia A, Zemel RA, Zhang Y, Gupta S, Alaoui A. Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan. Journal for ImmunoTherapy of Cancer. 2023;11:doi: 10.1136/jitc-2023-SITC2023.1418

Derry-Vick H, Shah NJ, Ahn J, DeAgresta B, Della Pia A, Zaemes JP, Pascual L, Arias-Orozco N, Zemel R, Sidarous G, Serzan M, Lev-Ari S, Alaoui A, Marki A, Nguyen K, Charalampous C, Rahman I, Wilkins O, Girgis M, Sridhar A, Adams D, Pecora AL, Atkins MB, Ip A. Associations Between Anxiety or Depression Diagnosis and Immune Checkpoint Inhibitor Outcomes. Cancer Med. 2025, Nov;14(21):e71326. PMCID: PMC12579804

Lev-Ari S, Serzan MT, Wu T, Krishnamurthy K, Adams S, Pascual L, Melinda W, Sinclaire B, Marafelias M, Alaoui A, Ahn J, Pecora A, Ip A, Atkins MB, Shah NJ. Association of Steroids and Other Immunosuppressive Agents on Efficacy of Immune checkpoint inhibitor therapy in patients with advanced melanoma. Society for Melanoma Research (SMR); Virtual, 2021. Oral Presentation

Ip A, Wang S, Cheruku D, Krishnamurthy K, Weber M, Sinclaire B, Paleoudis EG, Alaoui A, Lev-Ari S, Serzan MT, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Williams A, Ahn J, Pecora A, Atkins MB, Shah NJ. Late immune-related adverse events with immune checkpoint inhibitors. Journal of Clinical Oncology 2021 39:15_suppl, 2635-2635

Shah NJ, Wang S, Williams A, Weber M, Sinclaire B, Paleoudis EG, Alaoui A, Lev-Ari S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan MT, Cheruku D, Ahn J, Pecora A, Ip A, Atkins MB. Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-Caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases. Journal of Clinical Oncology. 2021, May;39.

Shah NJ, Al-shbool G, Blackburn M, Cook M, Belouali A, Ochoa S, Colton BS, Puthiamadathil J, Serzan MT, Knoedler AR, Liu SV, Pishvaian MJ, Mohebtash M, Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections. AACR Annual Meeting, Atlanta, 2019, Abstract ID#: 3230

Belouali A, Shah NJ, Krishnamurthy K, Wang S, Rao S, Gibney GT, Madhavan S, Atkins MB. A centralized comprehensive immune-oncology repository to enable outcomes and medication research. 7th Annual Big Data in Biomedicine Symposium at Georgetown University, Washington, DC, 2018 Abstract ID#: 6

Kelly WJ, Shah NJ, Serzan MT, Ma BT, Blackburn M, Ochoa S, Knoedler AR, Puthiamadathil JM, Santopietro A, Madhavan S, Belouali A, Rao S, Gardner KA, Rapisuwon S, Liu SV, Subramaniam DS, Atkins MB, Gibney GT. Characterization of Intracranial and Extra-cranial Progression in Patients with Solid Tumor Malignancy with Brain Metastasis Treated with Immune Checkpoint Inhibitors. 33rd SITC Annual Meeting, Washington, DC, 2018.

Shah NJ, Alsaadi D, Charabaty A, Atkins MB. A Case of Checkpoint Inhibitor-Induced Celiac Disease. 33rd SITC Annual Meeting, Washington, DC, 2018, Abstract ID#: P447

Pecora AL, Shah NJ, Jiang S, Atkins MB. Immunotherapy or targeted therapy-initial therapy for advanced melanoma: a real-world analysis. Society for Melanoma Research (SMR); Manchester, England, 2018. Abstract ID #: 134

Shah NJ, Puthiamadathil J, Serzan MT, et al. Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs). ESMO, Munich, Germany. 2018. Abstract ID#: 5960

Shah NJ, Ma BT, Kelly WJ, Belouali A, Serzan MT, Ochoa SG, Colton BS, Janni MM, Puthiamadathil J, Knoedler AR, Blackburn M, Madhavan S, Kumar PP, Liu SV, Gibney GT, Atkins MB. Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs). J Clin Oncol 36, 2018, (suppl; abstr e15074)

Belouali A, Shah NJ, Rao S, Zhu X, Gibney GT, Madhavan S, Atkins MB. A Centralized Comprehensive Immuno-Oncology Repository to enable Outcomes and Medication Research. 6th Annual Big Data in Biomedicine Symposium at Georgetown University, Washington, DC Georgetown ICBI 6th Annual Big Data in Biomedicine Symposium, 2017, Washington, DC

Shah NJ, Kelly WJ, Ma B, Zhou Y, Puthiamadathil J, Serzan MT, Subramaniam DS, Giaccone G, Tan MT, Liu SV. Impact of Steroids Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors. IASLC, 18th World Conference on Lung Cancer, Yokohama, Japan, 2017. Journal of Thoracic Oncology, 12, 11, S2148

Zhang Y, Gupta S, Belouali A, Lev-Ari S, Shah NJ, Krishnamurthy K, Serzan MT, Alaoui A, McGarvey P, Atkins MB, Madhavan S. Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models. J Immunother Cancer 2022;10(Suppl 2):A1-A1603

Derry-Vick H, Zaemes JP, Ahn J, Pascual L, Sinclaire B, Lev-Ari S, Alaoui A, Sridhar A, Adams D, Della Pia A, Pecora AL, Atkins MB, Ip A, Shah NJ. (06/2023). Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes. 2023 American Society of Clinical Oncology Annual Meeting (poster presentation). Chicago, IL.

Zhang Y, Lev-Ari S, Zaemes J, Della Pia A, DeAgresta B, Gupta S, Marki A, Zemel R, Ip A, Alaoui A, Charalampous C, Rahman I, Wilkins O, Madhavan S, McGarvey P, Pascual L, Atkins MB, Shah NJ. Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictions. JAMIA Open, Volume 8, Issue 4, August 2025, ooaf069

Gupta S, Belouali A, Shah N, Atkins M, Madhavan S. Identification of Patients with Immune-related Adverse Events from Clinical Notes using Machine Learning. 2020 IEEE International Conference on Healthcare Informatics (ICHI). 2020:1-2.

Gul A, Shah NJ, Mantia C, Hammers HJ, Ornstein MC, McDermott DF, Atkins MB, Rini BI. Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC). 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. J Clin Oncol. 2019;37(suppl).

Shah NJ, Blackburn M, Cook MR, Belouali A, Serzan M, Kelly W, Bikas A, Kim C, Madhavan S, Liu SV. Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections. 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

Ari SL, Zaemes J, Ozisik D, Zemel RA, Tan M, Pascual L, Sinclaire B, Alaoui A, DellaPia A, Pecora A. The impact of gender including female menopausal status on the safety and efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2023;11(Suppl 1), Abstract 615.

Zhang Y, Lev-Ari S, Shah NJ, Gupta S, Zaemes JP, Alaoui A, McGarvey P, Atkins MB. Immune-related adverse event prediction and influential factor identification. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Wilkins O, Marki A, Diamond E, Krishnamurthy K, Lev-Ari S, Alaoui A, Shah NJ, Sharma R, Atkins MB. Clinical characterization and association with autoimmunity in immune checkpoint inhibitor (ICI)-mediated thyroid dysfunction in a real-world sample. 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Wilkins O, Marki A, Diamond E, Zamudio K, Krishnamurthy K, Sharma R, Lev-Ari S, Alaoui A, Shah NJ, Atkins MB. Immune-mediated toxicities (irAEs) in immune checkpoint inhibitor (ICI) therapy in various combinations: A real-world sample. 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

Tian T, Shah NJ, Lev-Ari S, Alaoui A, Atkins MB, Zhang Y. Predicting immune-related adverse events (irAEs) with large language model (LLM) embeddings. 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.